Amgen’s betting it can raise awareness of multiple myeloma by sharing stories—and to do so, it’s enlisting the pros.

What's a pharma to do to keep new meds moving to market? Sell off as many of the old ones as possible, if the current trend is any clue—and Novartis has…

People with diabetes are waiting too long to discuss vision problems with their doctors, according to a new study funded by Bayer.

Tech billionaire Sean Parker’s startup Parker Institute for Cancer Immunotherapy has paired with the legacy Cancer Research Institute to advance development of…

With new IVI funding, Inovio plans to ratchet up research on its MERS vaccine, the only candidate against the virus now under testing in humans.

Adapt Pharma, maker of a nasal-spray naloxone product to treat opioid overdose, has hired McCann Health Canada to create its first ad campaign for the new med…

World drug spending heads for $1.5 trillion by 2021, report says, as new meds drive spending—and pricing debate spreads.

Teva's generics CEO, Siggi Olafsson, is jumping ship at a critical time, and analysts fear that the $40.5 billion Actavis integration will go off the…